The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.

Provided relates to the field of cytometry, specifically to flow cytometric methods and kits for improved diagnosis, prognosis and monitoring of tumors and other lesions involving immune cell infiltration. Further provided are embodiments of the subject matter which relate to compositions and methods providing high resolution quantitative means for immunophenotyping and immune modeling, and for identification of disease prognostic and therapy predictive biomarkers.

Provided herein, among other things, is a method for predicting how a patient responds to immunotherapy. In some embodiments, the method may comprise: performing a multiplexed binding assay on a tissue section of a tumor obtained from a cancer patient to identify at least cancer cells, effector immune cells and immunosuppressive cells in the tissue section; measuring, for each cell of a plurality of the effector immune cells: (i) the physical distance to its most proximal cancer cell; and (ii) the physical distances to its most proximal immunosuppressive cell; and calculating, for each of the effector immune cells analyzed, the ratio of the distance measured in step (i) and distance measured in step (ii), wherein the ratio is predictive of the patient's response to immunotherapy. The method may be used to select patients for immunotherapy.

Disclosed are compositions and methods for measuring the likelihood of recovery of a recently thawed immune cell. Methods include assaying the level of an ADAM-17-cleaved surface receptor expressed on the immune cells, wherein the level of the surface receptor directly correlates with the likelihood of immune cell recovery (i.e., the greater the increase of the expression level an ADAM-17-cleaved surface receptor relative to a control, the greater the likelihood of recovery). The method can be used to determine if immune cells have sufficient viability to be used in immunotherapy before use.

The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.

The present invention relates to a method for treating a subject having been diagnosed has having cancer with an immunotherapy is described. The method the following steps: a) providing a sample of a pharmaceutical product comprising T cells; b) analysing the reactivity of the sample T cells to an assay antigen; c) determining that said sample T cells meet a predetermined threshold for reactivity to the assay antigen; and d) if the sample T cells meet the predetermined threshold, administering the pharmaceutical product to the subject, wherein the pharmaceutical product comprise T cells isolated from a tumour sample from the subject, and wherein the T cells are tumour infiltrating lymphocytes (TILs).

Disclosed are isolated single heavy chain variable (V.sub.HH) monoclonal antibodies, antigen binding fragments thereof, and bispecific antibodies include these V.sub.HH monoclonal antibodies, wherein the V.sub.HH monoclonal antibody or antigen binding fragment specifically binds a canine programmed death (PD)-1. Nucleic acid molecules encoding these V.sub.HH monoclonal antibodies and antigen binding fragments are also disclosed, as are expression vectors including these nucleic acid molecules and host cells including these expression vectors. Methods of detecting canine PD-1, and methods of increasing cytotoxic T cell activity and treating tumors are also disclosed.